Contacto
Campos de conocimiento
Bioquímica
Farmacología
Neurobiología
Líneas de investigación
CANCER DE PULMON, MESOTELIOMA, TIMOMA
Publicaciones
4.172 Arrieta O, Barron F, Maldonado F, Cabrera L, Corona-Cruz JF, Blake M, Ramírez- Tirado LA, Zatarain-Barron ZL, Cardona AF, García O, Arén O, Dela Garza J. Radical consolidative Treatment provides a clinical benefit and long-term survival in patients with synchronous oligometastatic non-small cell lung cancer: A Phase II Study. Lung Cancer 130 (2019) 67-75. (Autor corresponsal: Oscar Arrieta) Factor de Impacto: 6.081
4.173. Arrieta O, Cardona AF, Bramuglia G, Cruz-Rico G, Corrales- Rodriguez L, Martín C, Castillo O, Cuello M, Rojas Bilbao E, Fernández C, Arén Frontera O, Denninghoff V, Recondo G, Avilés Salas A, Mas Lopez LA, Oblitas G, Rojas L, Piottante A, Sánchez Sosa S, Saenz J, Lupera H, Vargas C, Carranza H, Wills B, Pichelbaur E, on behalf of the CLICAP*. Molecular epidemiology of ALK rearrangements in advanced lung adenocarcinoma in Latin America. Oncology. 2019;96(4):207-216. (Autor corresponsal: Oscar Arrieta) Factor de Impacto: 3.734
4.174 A. F. Cardona, L. Rojas, · B. Wills · A. Ruiz‑Patiño, L. Abril, F. Hakim, E. Jiménez, N. Useche,S. Bermúdez, J. A. Mejía, J. F. Ramón, H. Carranza, C. Vargas, J. Otero, P. Archila, · J. Rodríguez, J. Behaine, D. González, J. Jacobo, H. Cifuentes, O. Feo, P. Penagos, D. Pineda, L. Ricaurte, L. E. Pino, C. Vargas, J. C. Marquez, M. I. Mantilla, L. D. Ortiz, C. Balaña, R. Rosell, Z. L. Zatarain‑Barrón, O. Arrieta. A comprehensive analysis of factors related to carmustine/ bevacizumab response in recurren gliobastoma.. Clin Transl Oncol. 2019 Oct;21(10):1364-1373 Factor de Impacto: 3.34
4.175 Lifshitz A, Arrieta O, Campillo C, Burgos R, Celis MÁ, Llata M, Domínguez J, Halabe J, Islas S, Jasso L, Moreno M, Plancarte R, Reyes-Sánchez A, Ruiz-Argüelles G, Soda A, Verástegui E, Sotelo J. Libertad de prescripción médica. Gac Med Mex. 2019;155(2):202-203. Factor de Impacto: 0.708
4.176 Arrieta O, Campillo C, Burgos R, Celis MÁ, Llata M, Domínguez J, Halabe J, Islas S, Jasso L1, Lifshitz A, Moreno M1, Plancarte R Reyes-Sánchez A, Ruiz-Argüelles GJ, Soda A, Verástegui E, Sotelo J. Importancia de la investigación clínica independiente en la medicina: dificultades y recomendaciones. Gac Med Mex. 2019;155(3):319-32. Factor de Impacto: 0.708
4.177. Beltrán-Anaya, Romero-Córdoba S, Rebollar-Vega, Arrieta O, Bautista-Piña V, Dominguez-Reyes C, Villegas-Carlos F, Tenorio-Torres A, Alfaro-Riuz L, Jiménez-Morales S, Cedro-Tanda A, Ríos-Romero M, Reyes-Grajeda JP, Tagliabue E, Iorio MV, Hidalgo-Miranda A. Expression pf long non-coding RNA ENSG00000226738 (LncKLHDC7B) is enriched in the immunomodulatory triple-negative breast cancer subtype amd its alteration promotes cell migration, invasion, and resistance to cell death. Mol Oncol. 2019 Apr; 13(4): 909–927. Factor de Impacto: 7.449
4.178. Barrón-Barrón F, Guzmán-De Alba E, Alatorre-Alexander J, Aldaco-Sarvider F, Bautista-Aragón Y, Blake-Cerda M, Blanco-Vázquez YC, Campos-Gómez S, Corona-Cruz JF, Iñiguez-García MA, Lozano-Ruiz FJ, Maldonado-Magos F, de la Mata-Moya D, Martínez-Barrera LM, Ramos-Prudencio R, Rodríguez-Cid J, Rivera-Rivera S, Trejo-Rosales RR, Aguilar-Ortíz MR, Astudillo-de la Vega H, Barajas-Figueroa LJ, Barroso-Quiroga N, Blanco-Salazar A, Castillo-Ortega G, Domínguez-Parra LM, Enriquez-Aceves MI, Fernández-Orozco A, Figueroa-Morales MA, Green-Schneewiss L, González-Garay JA, González Ramírez-Benfield R, Guadarrama-Orozco A, Guerrero-Ixtlahuac J, Hernández-Barajas D, Hernández-Montes de Oca R, Kelly-García J, Lázaro-León M, Silva-Bravo F, Tellez-Becerra JL, Macedo-Pérez EO, Maza-Ramos G, Mayorga-Butrón JL, Montaño-Velázquez BB, Murillo-Medina K, Narváez-Fernández S, Ochoa-Carrillo FJ, Olivares-Beltrán G, Olivares-Torres C, Ponce de León-Castillo M, Ponce-Viveros MA, Rubio-Gutiérrez JE, Sáenz-Frías JA, Silva-Vivas JA, Santillán-Doherty P, Soto-Ávila JJ, Toledo-Buenrostro V, Vargas-Abrego B, Velasco-Hidalgo L, Zapata-Tarres MM, Quintero-Beuló G, Arrieta O. National Clinical Practice Guidelines for the Management of Non-Small Cell Lung Cancer in Early, Locally Advanced and Metastatic Stages. Extended versión. Salud Publica Mex. Vol. 17(4):202-233. (Autor corresponsal: Oscar Arrieta) Factor de Impacto: 2.259
4.179. Rodríguez-Lara V, Ramírez-Tirado LA, Barrón F, Zatarain-Barrón ZL, Flores-Estrada D, Arrieta O. Characteristics of non-small cell lung cancer: differences by sex and hormonal status in a Mexican population. Salud Publica Mex. 2019 May-Jun;61(3):265-275. (Autor corresponsal: Oscar Arrieta) Factor de Impacto: 2.259
4.180 Charvel S, Cobo-Armijo F, Hernández-Ávila M, Reynales-Shigematsu LM, Salas J, Arrieta O, Santillán-Doherty P, Roldán-Xopa J, Pérez-Cuevas R, Escudero-de Los Ríos PM, Lluis Segú-Tolsa J. Needs in coverage and care for lung cancer in Mexico. Salud Publica Mex. 2019 May-Jun;61(3):339-346. Factor de Impacto: 2.259
4.181 Martín C, Cardona AF, Zatarain-Barrón ZL, Ruiz-Patiño A, Castillo O, Oblitas G, Corrales L, Lupinacci L, Pérez MA, Rojas L, González L, Chirinos L, Ortíz C, Lema M, Vargas C, Puparelli C, Carranza H, Otero J, Arrieta O. Real-World Treatment Patterns, Survival, and Prediction of CNS Progression in ALK-Positive Non-Small-Cell Lung Cancer Patients Treated with First-Line Crizotinib in Latin America. Oncology. 2018;94(5):297-305. (Autor corresponsal: Oscar Arrieta) Factor de Impacto: 3.734
4.182. Rojas L, Cardona AF, Trejo-Rosales R, Zatarain-Barrón ZL, Ramírez-Tirado LA, Ruiz-Patiño A, Campos Gómez S, Corrales L, Oblitas G, Bacon L, Martín C, de Lima VCC, Freitas HC, Mas L, Vargas C, Carranza H, Otero J, Pérez MA, González L, Chirinos L, Granados ST, Rodriguez J, Báez R, Remolina Bonilla YA, Núñez Cerrillo G, Archila P, Cuello M, Karachaliou N, Rosell R, Arrieta O; on behalf CLICaP. Characteristics and long-term outcomes of advanced pleural mesothelioma in Latin America (MeSO-CLICaP). Thorac Cancer. 2019 Jan 31. Factor de Impacto: 3.223
4.183. Cardona AF, Rojas L, Zatarain-Barrón ZL, Ruiz-Patiño A, Ricaurte L, Corrales L, Martín C, Freitas H, Cordeiro de Lima VC, Rodriguez J, Avila J, Bravo M, Archila P, Carranza H, Vargas C, Otero J, Barrón F, Karachaliou N, Rosell R, Arrieta O. Multigene mutation profiling and clinical characteristics of small-cell lung cancer in never-smokers versus heavy smokers (Geno1.3-CLICaP∫). Front Oncol. 2019 Apr 17;9:254. Factor de Impacto: 5.738
4.184 Cardona Andres F, Ricauter L, Zatarain-Barrón ZL, Arrieta O. Squamous Cell Lung Cancer: Genomic Evolution and Personalized Therapy. Salud Pública de México, 2019. Salud Publica Mex. 2019 May-Jun;61(3):329-338. Factor de Impacto: 2.259
4.185 Molina-Romero C, Arrieta O, Hernández-Pando R. Tuberculosis and lung cancer. Salud Publica Mex. 2019 May-Jun;61(3):286-291. Factor de Impacto: 2.259
4.186 Hernández-Pedro N, Soca-Chafre G, Alaez-Versón C, Carrillo-Sánchez K, Avilés-Salas A, Vergara E, Arrieta O. Mutational profile by targeted next generation sequencing of non-small cell lung cancer in the Mexican population. Salud Publica Mex. 2019 May-Jun;61(3):308-317. (Autor corresponsal: Oscar Arrieta) Factor de Impacto: 2.259
4.187 Gerson R, Zatarain-Barrón ZL, Blanco C, Arrieta O. Access to lung cancer therapy in the Mexican population: opportunities for reducing inequity within the health system. Salud Publica Mex. 2019 May-Jun;61(3):352-35. (Autor corresponsal: Oscar Arrieta) Factor de Impacto: 2.259
4.188 Cardona AF, Ruiz-Patiño A, Zatarain-Barrón ZL, Hakim F, Jiménez E, Mejía JA, Ramón JF, Useche N, Bermúdez S, Pineda D, Cifuentes H, Rojas L, Ricaurte L, Pino LE, Balaña C, Arrieta O. Systemic management of malignant meningiomas: A comparative survival and molecular marker analysis between Octreotide in combination with Everolimus and Sunitinib. Plos one. 2019 Jun 20;14(6):e0217340. Factor de Impacto: 3.752
4.189 Arrieta O, Barrón F, Salinas Padilla MA, Avilés-Salas A, Ramirez-Tirado LA, Arguelles Jiménez MJ, Vergara E, Zatarain-Barrón ZL, Hernández-Pedro N, Cardona AF, Cruz-Rico G, Barrios-Bernal P, Yamamoto Ramos M, Rosell R. Effect of Metformin Plus Tyrosine Kinase Inhibitors Compared With Tyrosine Kinase Inhibitors Alone in Patients With Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma: A Phase 2 Randomized Clinical Trial. JAMA Oncol. 2019 Sep 5:e19255. (Autor corresponsal: Oscar Arrieta) Factor de Impacto: 33.06
4.190 Arrieta O, Zatarain-Barrón ZL Aldaco F, Barrón F, Báez-Saldaña R, Campos-Gómez S, Trejo R, De la Garza J. Lung Cancer in Mexico. J. Thorac Oncol . 2019 Oct;14(10):1695-1700. (Autor corresponsal: Oscar Arrieta) Factor de Impacto: 20.121
4.191 Menéndez-Aponte y Guzman R, Turcott J, De la Piedra A, Sandoval-Eslava VM, Tarditi-Ruiz G, Ilse M. Tapia-Garduño, De la Torre-Madrid I, Gallegos-Figueroa I, Arrieta O. Effect of Complementary Integrative Oncology on Anxiety, Depression and Quality of Life in Thoracic Cancer Patients: A Pilot Study. The Journal Complementary Therapies in Clinical Practice. 2019. Aug;36:56-63. (Autor corresponsal: Oscar Arrieta) Factor de Impacto: 3.577
4.192 Ramírez-Tirado LA, Uribe-Ortiz CE, Arrieta O, Tirado-Gómez LL. Lung cancer mortality and municipal marginalization in Mexico, 1998-2016. Salud Publica Mex. 2019 May-Jun;61(3):249-256. Factor de Impacto: 2.259
4.193 Castillero F, Castillo-Fernández O, Jiménez-Jiménez G, Fallas-Ramírez J, Peralta-Álvarez MP, Arrieta O. Cancer immunotherapy-associated hypophysitis. Future Oncol. 2019 Aug 19. (Autor corresponsal: Oscar Arrieta) Factor de Impacto: 3.674
4.194 Arrieta O, Lazcano E. Lung cancer. Epidemiology, diagnosis and treatment.
Salud Publica Mex. 2019 May-Jun;61(3):217-218. (Autor corresponsal: Oscar Arrieta) Factor de Impacto: 2.259
4.195 Turcott JG, Juárez-Hernández E, Sánchez-Lara K, Flores-Estrada D, Zatarain-Barrón ZL, Arrieta O. Baseline Dysgeusia in Chemotherapy-Naïve Non-Small Cell Lung Cancer Patients: Association with Nutrition and Quality of Life. Nutr Cancer. 2020; 72 (2):194-201. (Autor corresponsal: Oscar Arrieta) Factor de Impacto: 2.816
4.196 Arrieta O, Escamilla-López I, Lyra-González I, Barrón F, Ramírez-Tirado LA, Vergara E, Corona-Cruz JF, Maldonado F, Jiménez-Fuentes E. Radical aggressive treatment among non-small cell lung cancer patients with malignant pleural effusion without extra-thoracic disease. J Thorac Dis. 2019 Feb;11(2):595-601. (Autor corresponsal: Oscar Arrieta) Factor de Impacto: 3.005
4.197 Cacho-Díaz B, Spínola-Maroño H, Mendoza-Olivas LG, Monroy-Sosa A, Reyes-Soto G, Arrieta O. Association of neurologic manifestations and CEA levels with the diagnosis of brain metastases in lung cancer patients. Clin Transl Oncol. 2019. Factor de Impacto: 3.34
4.198 Sotelo-Rodríguez DC, Ruíz-Patiño A, Ricaurte L, Arrieta O, Zatarain-Barrón ZL, Cardona AF1. Challenges and shifting paradigms in clinical trials in oncology: the case for immunological and targeted therapies. Ecancer medical science. 2019 Jul 5;13:936. Factor de Impacto: 0.0
4.199 Soca-Chafre G, Montiel-Dávalos A, Rosa-Velázquez IA, Caro-Sánchez CHS, Peña-Nieves A, Arrieta O. Multiple Molecular Targets Associated with Genomic Instability in Lung Cancer. Int J Genomics. 2019 Jul 1;2019:9584504.:1-8. (Autor corresponsal: Oscar Arrieta) Factor de Impacto: 2.758
4.200 Hernandez-Martinez JM, Sánchez-Reyes R, De la Garza-Salazar JG, Arrieta O.
Onco-omics Approaches and Applications in Clinical Trials for Cancer Patients. Adv Exp Med Biol. 2019;1168:79-90.:1-9. (Autor corresponsal: Oscar Arrieta) Factor de Impacto: 17.93
4.201 Ruiz-Patiño A, Arrieta O, Cardona AF, Martín C, Raez LE, Zatarain-Barrón ZL, Barrón F, Ricaurte L, Bravo-Garzón MA, Mas L, Corrales L, Rojas L, Lupinacci L, Perazzo F, Bas C, Carranza O, Puparelli C, Rizzo M, Ruiz R, Rolfo C, Archila P, Rodríguez J, Sotelo C, Vargas C, Carranza H, Otero J, Pino LE, Ortíz C, Laguado P, Rosell R; CLICaP. Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non-small cell lung cancer (NSCLC) compared with chemotherapy (Quijote-CLICaP). Thorac Cancer . 2020 Feb;11(2):353-361. Factor de Impacto: 3.223
4.202 Rosell R, Karachaliou N, Arrieta O. Novel molecular targets for the treatment of lung cancer. Curr Opin Oncol. 2020 Jan;32(1):37-43. Factor de Impacto: 3.915
4.203 Lozano Ruiz FJ, Ileana Pérez Álvarez S, Poitevin Chacón MA, Maldonado Magos F, Prudencio RR, Cabrera Miranda L, Arrieta O. The importance of image guided radiotherapy in small cell lung cancer: Case report and review of literature. Rep Pract Oncol Radiother. 2020 Jan-Feb;25(1):146-149. Factor de Impacto: 0.0
4.204 Arrieta O, Aviles-Salas A, Orozco-Morales M, Hernández-Pedro N, Cardona AF, Cabrera-Miranda L, Barrios-Bernal P, Soca-Chafre G, Cruz-Rico G, Peña-Torres ML, Moncada-Claudio G, Ramirez-Tirado LA. Association between CD47 expression, clinical characteristics and prognosis in patients with advanced non-small cell lung cancer. Cancer Med. 2020 Apr;9(7):2390-2402. (Autor corresponsal: Oscar Arrieta) Factor de Impacto: 4.711
4.205 Corrales L, Rosell R, Cardona AF, Martín C, Zatarain-Barrón ZL, Arrieta O. Lung cancer in never smokers: The role of different risk factors other than tobacco smoking. Crit Rev Oncol Hematol 2020 Apr;148:10289 1-8. (Autor corresponsal: Oscar Arrieta) Factor de Impacto: 6.625
4.206 Arrieta O, Ramírez-Tirado LA, Caballé-Perez E, Mejia-Perez A, Zatarain-Barrón ZL, Cardona AF, Lozano-Ruíz F, Segura-González M, Cruz-Rico G, Maldonado F, Rosell R. Response rate of patients with baseline brain metastases from recently diagnosed non-small cell lung cancer receiving radiotherapy according to EGFR, ALK and KRAS mutation status. Thorac Cancer. 2020 Apr;11(4):1026-1037. (Autor corresponsal: Oscar Arrieta) Factor de Impacto: 3.223
4.207 López-Salazar J, Ramírez-Tirado LA, Gómez-Contreras N, Pacheco-Bravo I, Cortés E, Gallardo D, Arrieta O, Cesarman-Maus G. Cancer-associated prothrombotic pathways: leucocytosis, but not thrombocytosis, correlates with venous thromboembolism in women with ovarian cancer. Intern Med J. 2020 Mar;50(3):366-370. Factor de Impacto: 2.611
4.208 Arrieta O, Ramirez-Tirado LA, Zatarain-Barrón ZL. Metformin Plus Tyrosine Kinase Inhibitors in Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer-Reply. (Autor corresponsal: Oscar Arrieta) JAMA Oncol . 2020 May 1;6(5):782-783 Factor de Impacto: 33.006
4.209 Arrieta O, Zatarain-Barrón ZL, Cardona AF. New opportunities in a challenging disease: lurbinectedin for relapsed small-cell lung cancer. (Autor corresponsal: Oscar Arrieta) Lancet Oncol . 2020 May;21(5):605-607 Factor de Impacto: 54.433
4.210 Arrieta O, Barrón F, Ramírez-Tirado LA, Zatarain-Barrón ZL, Cardona AF, Díaz-García D, Yamamoto Ramos M, Mota-Vega B, Carmona A, Peralta Álvarez MP, Bautista Y, Aldaco F, Gerson R, Rolfo C, Rosell R. Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer: The PROLUNG Phase 2 Randomized Clinical Trial. JAMA Oncol . 2020 Apr 9;6(6):1-9. (Autor corresponsal: Oscar Arrieta) Factor de Impacto: 33.006
4.211 Muñoz-Montaño W, Cabrera-Galeana P, Alvarado-Miranda A, Villarreal-Garza C, Mohar A, Olvera A, Bargallo-Rocha E, Lara-Medina F, Arrieta O. Prognostic Value of the Pretreatment Neutrophil-to-Lymphocyte Ratio in Different Phenotypes of Locally Advanced Breast Cancer During Neoadjuvant Systemic Treatment. Clin Breast Cancer
2020 Aug;20(4):307-316. (Autor corresponsal: Oscar Arrieta) Factor de Impacto: 3.078
4.212 Cardona AF, Ruiz-Patiño A, Ricaurte L, Zatarain-Barrón ZL, Barrón F, Arrieta O. Chronic and Severe Non-Lichenoid Oral Ulcers Induced by Nivolumab - Diagnostic and Therapeutic Challenge: A Case Report. Case Rep Oncol. 2020 Mar 25;13(1):314-320. Factor de Impacto: 0.0
4.213 Ruiz-Patiño A, Arrieta O, Pino LE, Rolfo C, Ricaurte L, Recondo G, Zatarain-Barron ZL, Corrales L, Martín C, Barrón F, Vargas C, Carranza H, Otero J, Rodriguez J, Sotelo C, Viola L, Russo A, Rosell R, Cardona AF. Mortality and Advanced Support Requirement for Patients With Cancer With COVID-19: A Mathematical Dynamic Model for Latin America. JCO Glob Oncol . 2020 May;6:752-760. Factor de Impacto: 0.0
4.214 Turcott JG, Martinez-Samano JE, Cardona AF, Bassarmal SS, Ramírez-Tirado LA, Zatarain-Barrón ZL, Barrón F, Corrales L, Martín C, Barragán-Castillo PA, Ruiz-Patiño A, Flores-Estrada D, Arrieta O. The Role of a Cachexia Grading System in Patients with Non-Small Cell Lung Cancer Treated with Immunotherapy: Implications for Survival. Nutr Cancer. 2020 Jun 1;1-8. (Autor corresponsal: Oscar Arrieta) Factor de Impacto: 2.816
4.215 Raez LE, Cardona AF, Arrieta O, Lopes G. Lung Cancer Disparities in Hispanics: Molecular Diagnosis and Use of Immunotherapy. JCO Glob Oncol . 2020 Jun;6:784-788. Factor de Impacto: 0.0
4.216 Ruiz-Patiño A, Cardona AF, Arrieta O, Rolfo C, Gómez HL, Raez LE, Lopes G, Zatarain-Barrón ZL, Ricaurte L, Zamudio-Molano N, Rangel V, Oviedo J, Solano MP, Rojas L, Corrales L, Martín C, Mas L, Cuello M, Barrón F, Otero J, Carranza H, Vargas C, Rosell R. Scientific publications in cancer: in Latin America, strong scientific networks increase productivity (the TENJIN study). J Clin Epidemiol . 2020 Jun 12;126:1-8. Factor de Impacto: 7.407
4.217 Cardona AF, Arrieta O, Ruiz-Patiño A, Sotelo C, Zamudio-Molano N, Zatarain-Barrón ZL, Ricaurte L, Raez L, Álvarez MPP, Barrón F, Rojas L, Rolfo C, Karachaliou N, Molina-Vila MA, Rosell R. Precision medicine and its implementation in patients with NTRK fusion genes: perspective from developing countries. Ther Adv Respir Dis . Jan-Dec 2020;14: 1-16. Factor de Impacto: 5.158
4.218 Arrieta O, Cardona AF, Lara-Mejía L, Heredia D, Barrón F, Zatarain-Barrón ZL, Lozano F, de Lima VC, Maldonado F, Corona-Cruz F, Ramos M, Cabrera L, Martin C, Corrales L, Cuello M, Arroyo-Hernández M, Aman E, Bacon L, Baez R, Benitez S, Botero A, Burotto M, Caglevic C, Ferraris G, Freitas H, Kaen DL, Lamot S, Lyons G, Mas L, Mata A, Mathias C, Muñoz A, Patane AK, Oblitas G, Pino L, Raez LE, Remon J, Rojas L, Rolfo C, Ruiz-Patiño A, Samtani S, Viola L, Viteri S, Rosell R. Recommendations for detection, prioritization, and treatment of thoracic oncology patients during the COVID-19 pandemic: the THOCOoP cooperative group. Crit Rev Oncol Hematol . 2020 Jun 20;153:103033. (Autor corresponsal: Oscar Arrieta) Factor de Impacto: 6.625
4.219 Corona-Cruz J, Alba EG, Iñiguez-García M, López-Saucedo R, Olivares-Torres C, Rodriguez-Cid J, Salazar-Otaola G, Martínez-Said H, Flores RM, Arrieta O. Surgical care of thoracic malignancies during the COVID-19 pandemic in México: An expert consensus guideline from the Sociedad Mexicana de Oncología (SMeO) and the Sociedad Mexicana de Cirujanos Torácicos Generales (SMCTG). Thoracic Cancer 11 (2020) 2370–2375 Factor de Impacto: 3.223
4.220 Rolfo C, Cardona AF, Ruiz-Patiño A, Ariza S, Zatarain-Barron L, Pino LE, Viola L, Russo A, Rojas L, Ricaurte L, Arrieta O. Atypical skin manifestations during immune checkpoint blockage in COVID19-infected lung cancer patients. J Thorac Oncol . 2020 VOL. 15 No. 11 1767-72 Factor de Impacto: 20.121
4.221 Ruiz-Patiño A, Barrón F, Cardona AF, Corrales L, Mas L, Martín C, Zatarain-Barrón ZL, Recondo G, Ricaurte L, Rojas L, Archila P, Rodríguez J, Sotelo C, Viola L, Vargas C, Carranza H, Otero J, Pino LE, Rolfo C, Rosell R, Arrieta O; CLICaP. Antibiotics impair immune checkpoint inhibitor effectiveness in Hispanic patients with non-small cell lung cancer (AB-CLICaP). Thorac Cancer. 2020 Jul 24 Factor de Impacto: 3.223
4.222García-Pérez FO, Medina-Ornelas SS, Barron-Barron F, Arrieta-Rodriguez O.
Evaluation of non-small cell lung cancer by PET/CT with 64 CuCl 2: initial experience in humans. Am J Nucl Med Mol Imaging . 2020 Jun 15;10(3):143-150. Factor de Impacto: 0.0
4.223.- Rosell R, Karachaliou N, Fancelli S, Arrieta O, Troncone G, Cao P. Proprotein convertase furin in SARS-CoV-2 and non-small cell lung cancer. Transl Lung Cancer Res. 2020 Aug;9(4):945-947. Factor de Impacto: 4.726
4.224 Catalán R, Orozco-Morales M, Hernández-Pedro NY, Guijosa A, Colín-González AL, Ávila-Moreno F, Arrieta O. CD47-SIRP α Axis as a Biomarker and Therapeutic Target in Cancer: Current Perspectives and Future Challenges in Nonsmall Cell Lung Cancer. J Immunol Res. 2020 Sep 19;2020:9435030. (Autor corresponsal: Oscar Arrieta) Factor de Impacto: 4.493
4.225 Arrieta O, Lara-Mejía L, Zatarain-Barrón ZL. Carboplatin plus etoposide or topotecan for small-cell lung cancer. (Autor corresponsal: Oscar Arrieta) Lancet Oncol. 2020 Sep;21(9):1132-1134. Factor de Impacto: 54.433
4.226 Arrieta O, Catalán R, Guzmán-Vazquez S, Barrón F, Lara-Mejía L, Soto-Molina H, Ramos-Ramírez M, Flores-Estrada D, de la Garza J. Cost-effectiveness analysis of first and second-generation EGFR tyrosine kinase inhibitors as first line of treatment for patients with NSCLC harboring EGFR mutations. BMC Cancer. 2020 Sep 1;20(1):829. (Autor corresponsal: Oscar Arrieta) Factor de Impacto: 4.638
4.227 Orozco-Morales M, Hernández-Pedro NY, Barrios-Bernal P, Arrieta O, Ruiz-Godoy LM, Aschner M, Santamaría A, Colín-González AL. S-allylcysteine induces cytotoxic effects in two human lung cancer cell lines via induction of oxidative damage, downregulation of Nrf2 and NF-κB, and apoptosis. Anticancer Drugs. 2020 Oct 28
Factor de Impacto: 2.389
4.228 Heredia D, Barrón F, Cardona AF, Campos S, Rodriguez-Cid J, Martinez-Barrera L, Alatorre J, Salinas MÁ, Lara-Mejia L, Flores-Estrada D, Arrieta O. Brigatinib in ALK-positive non-small cell lung cancer: real-world data in the Latin American population (Bri-world extend CLICaP). (Autor corresponsal: Oscar Arrieta) Future Oncol . 2021 Jan;17(2):169-181 Factor de Impacto: 3.674
4.229 Arrieta O, Lozano-Ruiz F, Blake-Cerda M, Catalán R, Lara-Mejía L, Salinas MÁ, Maldonado-Magos F, Corona-Cruz JF. Locoregional control and toxicity after pleurectomy/decortication and intensity-modulated pleural radiation therapy in patients with malignant pleural mesothelioma. (Autor corresponsal: Oscar Arrieta) Factor de Impacto: 3.223
4.230 Barrón F, Sánchez R, Arroyo-Hernández M, Blanco C, Zatarain-Barrón ZL, Catalán R, Ramos-Ramírez M, Cardona AF, Flores-Estrada D, Arrieta O. Risk of Developing Checkpoint Immune Pneumonitis and Its Effect on Overall Survival in Non-small Cell Lung Cancer Patients Previously Treated With Radiotherapy. Front Oncol . 2020 Sep 29;10:570233. (Autor corresponsal: Oscar Arrieta) Factor de Impacto: 5.738
4.231 Garcia-Campelo R, Arrieta O, Massuti B, Rodriguez-Abreu D, Granados ALO, Majem M, Vicente D, Lianes P, Bosch-Barrera J, Insa A, Dómine M, Reguart N, Guirado M, Sala MÁ, Vázquez-Estevez S, Caro RB, Drozdowskyj A, Verdú A, Karachaliou N, Molina-Vila MA, Rosell R; Spanish Lung Cancer Group (SLCG). Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A multicenter, randomized phase II study (GOAL). Lung Cancer. 2020 Oct 3;150:62-69. Factor de Impacto: 6.081
4.232 Russo A, Cardona AF, Caglevic C, Manca P, Rui-Patiño A, Arrieta O, Rolfo C. Overcoming TKI resistance in fusión-drive NSCLC: new generation inhibitors and rationale for combination strategies. Transl Lung Cancer Res 2020,9(6):2581-2598. Factor de Impacto: 4.726
4.233 Herrera-Solorio AM, Peralta-Arrieta I, Armas López L, Hernández-Cigala N, Mendoza Milla C, Ortiz Quintero B, Catalán Cárdenas R, Pineda Villegas P, Rodríguez Villanueva E, Trejo Iriarte CG, Zúñiga J, Arrieta O, Ávila-Moreno F. LncRNA SOX2-OT regulates AKT/ERK and SOX2/GLI-1 expression, hinders therapy, and worsens clinical prognosis in malignant lung diseases. Mol Oncol. 2020 Dec 8 Factor de Impacto: 7.449
4.234 Blake-Cerda M, Lozano-Ruíz F, Maldonado-Magos F, de la Mata-Moya D, Díaz-García D, Lara-Mejía L, Zatarain-Barrón ZL, Cuevas-Góngora MF, Barron-Barron F, Corona-Cruz JF, Cabrera-Miranda L, Arroyo-Hernández M, Gerson R, Arrieta O. Consolidative stereotactic ablative radiotherapy (SABR) to intrapulmonary lesions is associated with prolonged progression-free survival and overall survival in oligometastatic NSCLC patients: A prospective phase 2 study. Lung Cancer. 2021 Feb;152:119-126. (Autor corresponsal: Oscar Arrieta) Factor de Impacto: 6.081
4.235 Angel MO, Colombo Bonadio R, Harada G, Waisberg F, Enrico D, Arrieta O, Corrales L, Martin C, Werutsky G, Barrios C, Ricaurte L, Cardona AF; Latin American Consortium for Lung Cancer Investigation (CLICaP) and Latin American Oncology Group (LACOG). Mentoring as an opportunity to improve research and cancer care in Latin America (AAZPIRE project). ESMO Open. 2020 Nov;5(6):e000988. Factor de Impacto: 6.883
4.236 Cardona AF, Ruiz-Patiño A, Arrieta O, Ricaurte L, Zatarain-Barrón ZL, Rodriguez J, Avila J, Rojas L, Recondo G, Barron F, Archila P, Sotelo C, Bravo M, Zamudio N, Corrales L, Martín C, Rolfo C, Viola L, Carranza H, Vargas C, Otero J, Bermudez M, Gamez T, Pino LE, Rosell R. Genotyping Squamous Cell Lung Carcinoma in Colombia (Geno1.1-CLICaP). Front Oncol . 2020 Dec 15;10:588932. Factor de Impacto: 5.738
4.237 Domínguez J, Verástegui E, Arrieta O, Burgos R, Campillo C, Celis MÁ, Llata M, Halabe J, Islas S, Jasso L, Lifshitz A, Moreno M, Plancarte R, Reyes-Sánchez A, Ruiz-Argüelles G, Soda A, Sotelo J. Recommendations for the sale and promotion of dermocosmetic treatments at the office. Gac Med Mex . 2020;156(5):467-468. Factor de Impacto: 0.708
4.238 Muñiz-Hernández S, Velázquez-Fernández JB, Díaz-Chávez J, Mondragón-Fonseca O, Mayén-Lobo Y, Ortega A, López-López M, Arrieta O. STRA6 Polymorphisms Are Associated With EGFR Mutations in Locally-Advanced and Metastatic Non-Small Cell Lung Cancer Patients. Front Oncol. 2020 Nov 24;10:579561. (Autor corresponsal: Oscar Arrieta) Factor de Impacto: 5.738
4.239 Carrot-Zhang J, Soca-Chafre G, Patterson N, Thorner AR, Nag A, Watson J, Genovese G, Rodriguez J, Gelbard MK, Corrales-Rodriguez L, Mitsuishi Y, Ha G, Campbell JD, Oxnard GR, Arrieta O, Cardona AF, Gusev A, Meyerson M. Genetic ancestry contributes to somatic mutations in lung cancers from admixed Latin American populations. Cancer Discov . 2021 Mar;11(3):591-598. (Autor corresponsal: Oscar Arrieta) Factor de Impacto: 38.272
4.240 Karachaliou, N, Arrieta O, Giménez-Capitán A.,Aldeguer E, Drozdowskyj, A Chaib I, Reguart N, Garcia-Campelo R, Chen J_H, Molina-Vila M Rosell R, On behalf of the Spanish Lung Cancer Group (SLCG). BRCA1 expression and outcome in EGFR-mutant NSCLC patients treated with gefitinib alone or in combination with olaparib. JTO Clinical and Research Reports Volume 2, Issue 3, March 2021, 100113. Factor de Impacto: 0.0
4.241. Maldonado F, Gonzalez-Ling A,. Oñate-Ocaña LF, Cabrera-Miranda L., Zatarain-Barrón ZL,. Turcott J, Flores-Estrada D, Lozano-Ruiz F, Cacho-Díaz B, Arrieta O. Prophylactic Cranial Irradiation in high-risk metastatic non-small cell lung cancer patients: Quality of life and neurocognitive analysis of a randomized phase II study. Int J Radiat Oncol Biol Phys . 2021 Sep 1;111(1):81-92 Autor corresponsal: Oscar Arrieta) Factor de Impacto: 8.013
4.242 Arrieta O, Maldonado F,. Turcott JG, Zatarain-Barrón ZL, Barrón F, Blake-Cerda M, Cabrera-Miranda LA,. Cardona F, De La Garza J, Rosell R. Prophylactic Cranial Irradiation reduces brain metastases and improves overall survival in high-risk metastatic non-small cell lung cancer patients: a randomized phase II study (PRoT-BM trial). Int. J. . Int J Radiation Oncol Biol Phys, Vol. 110, No. 5, pp. 1442-1450, 2021 February 2021. (Autor corresponsal: Oscar Arrieta) Factor de Impacto: 8.013
4.243 Martín, C, Enrico D, Mas L, Patane A, Arrieta O, Soria T,. Cardona AF, Ruiz-Patiño A, Ruiz R, Rioja P, LozanoS, Zatarin-Barrón ZL, Barrón F, Puparelli C, Tsou F, . 33Corassa M, Helano C. Freitas, Cordeiro de Lima C, Rojas L, Ordóñez-Reyes C, Corrales C, on behalf of CLICaP etal. Characteristics and outcomes of thymomas in Latin America: results from over 10 years of experience (CLICaP-LATimus). Thorac Cancer. 2021;12:1328–1335. Factor de Impacto: 3.223
4.244 Arrieta O, Varela-Santoyo E, Cardona AF, Sánchez-Reyes R, Lara-Mejía L, Bassarmal SS, Valle-Bautista D, Corrales-Rodríguez L, Motola-Kuba D, Cabrera-Miranda L, Martín C. Association of Carcinoembryonic Antigen Reduction With Progression-free and Overall Survival Improvement in Advanced Non-small-cell Lung Cancera, Luis Corrales-Rodríguez, Daniel Motola-Kuba,Luis Cabrera-Miranda, Claudio Martín. Clin Lung Cancer . 2021 Nov;22(6):510-522 Factor de Impacto: 4.84
4.245 Arroyo-Hernández M, Maldonado F, Lozano-Ruiz F, Muñoz-Montaño W, Nuñez-Baez M, Arrieta O. Radiation-induced lung injury: current evidence. BMC Pulm Med. 2021 Jan 6;21(1):9 Factor de Impacto: 4.638
4.246 Borghaei H, Gettinger S, Vokes EE, Chow LQM, Burgio MA, de Castro Carpeno J, Pluzanski A, Arrieta O, Frontera OA, Chiari R, Butts C, Wójcik-Tomaszewska J, Coudert B, Garassino MC, Ready N, Felip E, García MA, Waterhouse D, Domine M, Barlesi F, Antonia S, Wohlleber M, Gerber DE, Czyzewicz G, Spigel DR, Crino L, Eberhardt WEE, Li A, Marimuthu S, Brahmer J. Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer J Clin Oncol. 2021 Mar 1;39(7):723-733.
4.247. Arrieta O, Salas AA, Cardona AF, Díaz-García D, Lara-Mejía L, Escamilla I, García AP, Pérez EC, Raez LE, Rolfo C, Rosell R. Risk of development of brain metastases according to the IASLC/ATS/ERS lung adenocarcinoma classification in locally advanced and metastatic disease Lung Cancer. 2021 May;155:183-190
4.248 Rodríguez J, Avila J, Rolfo C, Ruíz-Patiño A, Russo A, Ricaurte L, Ordóñez-Reyes C, Arrieta O, Zatarain-Barrón ZL, Recondo G, Cardona AF. When Tissue is an Issue the Liquid Biopsy is Nonissue: A Review. Oncol Ther. 2021 Jun;9(1):89-110
4.249 Cardona AF, Ruiz-Patiño A, Zatarain-Barron ZL, Ariza S, Ricaurte L, Rolfo C, Arrieta O. Refractory Bullous Pemphigoid in a Patient with Metastatic Lung Adenocarcinoma Treated with Pembrolizumab. Case Rep Oncol . 2021 Mar 10;14(1):386-39
4.250 Zatarain-Barrón ZL, Cardona AF, Díaz-García D, Trejo Rosales R, Rojas L, Cruz-Rico G, Nagy R, Cabrera L, Vargas C, Saam J, Barrón F, Arrieta O. Cell-Free Circulating Tumor DNA Improves Standard Genotyping of Non-Small-Cell Lung Cancer and Increases Detection of Targetable Alterations in a Selected Hispanic Cohort. Oncology. 2021;99(8):539-546
4.251 Lara Gongora AB, Werutsky G, Jardim DL, Nogueira-Rodrigues A, Barrios CH, Mathias C, Maluf F, Riechelmann R, Fraga M, Gomes H, William WN, Yamada CAF, de Castro G Jr, Rosa DD, de Melo AC, Sala R, Bustamante E, Bretel D, Arrieta O, Cardona AF, Bastos DA. Impact of the COVID-19 Pandemic on Oncology Clinical Research in Latin America (LACOG 0420) . JCO Glob Oncol. 2021 Apr;7:649-658
4.252. Arrieta O, Muñoz-Montaño W, Muñiz-Hernández S, Campos S, Catalán R, Soto-Molina H, Guzmán Vázquez S, Díaz-Álvarez O, Martínez-Pacheco V, Turcott JG, Ramos-Ramírez M, Cabrera-Miranda L, Barrón F, Cardona AF. Efficacy, Safety, and Cost-Minimization Analysis of Continuous Infusion of Low-Dose Gemcitabine Plus Cisplatin in Patients With Unresectable Malignant Pleural Mesothelioma. Front Oncol. 2021 Apr 20;11:641975
4.253 Arrieta O, Hernández-Martínez JM, Montes-Servín E, Heredia D, Cardona AF, Molina-Romero C, Lara-Mejía L, Diaz-Garcia D, Bahena-Gonzalez A, Mendoza-Oliva DL. Impact of detecting plasma EGFR mutations with ultrasensitive liquid biopsy in outcomes of NSCLC patients treated with first- or second-generation EGFR-TKIs. Cancer Biomark . 2021;32(2):123-135
4.254 Muñoz-Montaño WR, Cabrera-Galeana P, De la Garza-Ramos C, Azim HA Jr, Tabares A, Perez V, Porras Reyes F, Sanchez Benitez D, Alvarado-Miranda A, Lara-Medina F, Vazquez Romo R, Bargallo-Rocha E, Arrieta O, Villarreal-Garza C. Prognosis of breast cancer diagnosed during pregnancy and early postpartum a{{ccording to immunohistochemical subtype: A matched case-control study. Breast Cancer Res Treat. 2021 Jul;188(2):489-500
4.255 Báez-Saldaña R, Canseco-Raymundo A, Ixcot-Mejía B, Juárez-Verdugo I, Escobar-Rojas A, Rumbo-Nava U, Castillo-González P, León-Dueñas S, Arrieta O. Case-control study about magnitude of exposure to wood smoke and risk of developing lung cancer. Eur J Cancer Prev. 2021 Nov 1;30(6):462-468
4.256 Orozco-Morales M, Avilés-Salas A, Hernández-Pedro N, Catalán R, Cruz-Rico G, Colín-González AL, Dosal-Mancilla E, Barrios-Bernal P, Arrieta O. Clinicopathological and Prognostic Significance of CD47 Expression in Lung Neuroendocrine Tumors. J Immunol Res. 2021 Jun 11;2021:6632249
4.257 Cruz-Rico G, Avilés-Salas A, Popa-Navarro X, Lara-Mejía L, Catalán R, Sánchez-Reyes R, López-Sánchez D, Cabrera-Miranda L, Aquiles Maldonado-Martínez H, Samtani-Bassarmal S, Arrieta O. Association of Lung Adenocarcinoma Subtypes According to the IASLC/ATS/ERS Classification and Programmed Cell Death Ligand 1 (PD-L1) Expression in Tumor Cells. Pathol Oncol Res. 2021 Apr 8;27:597499.
4.258 Muñoz-Montaño W, Muñiz-Hernández S, Avilés-Salas A, Catalán R, Lara-Mejía L, Samtani-Bassarmal S, Cardona AF, Mendoza-Desión J, Hernández-Cueto D, Maldonado A, Baay-Guzmán G, Huerta-Yepes S, Arrieta O. RRM1 and ERCC1 as biomarkers in patients with locally advanced and metastatic malignant pleural mesothelioma treated with continuous infusion of low-dose gemcitabine plus cisplatin. BMC Cancer. 2021 Aug 5;21(1):892
4.259 Soto-Perez-de-Celis E, Arrieta O, Bargalló-Rocha E, Campos-Gómez S, Chavarri-Guerra Y, Chávez-Nogueda J, González-Lara F, Pérez-Jacobo F, Martínez-Said H. COVID-19 Vaccine Guidance for Patients with Cancer in Mexico: Report From the Working Group of the Mexican Society of Oncology. Arch Med Res . 2022 Feb;53(2):223-227
4.260 Rosell R, Cardona AF, Arrieta O, Aguilar A, Ito M, Pedraz C, Codony-Servat J, Santarpia M. Coregulation of pathways in lung cancer patients with EGFR mutation: therapeutic opportunities. Br J Cancer . 2021 Dec;125(12):1602-1611
4.261 Addeo A, Friedlaender A, Giovannetti E, Russo A, de Miguel-Perez D, Arrieta O, Cardona AF, Rolfo C. A New Generation of Vaccines in the Age of Immunotherapy
Curr Oncol Rep. 2021 Nov 4;23(12):137.
4.262 Rosell R, Karachaliou N, Fancelli S, Arrieta O, Troncone G, Cao P. Proprotein convertase furin in SARS-CoV-2 and non-small cell lung cancer. Transl Lung Cancer Res. 2020 Aug;9(4):945-947.
4.263 Russo A, Cardona AF, Caglevic C, Manca P, Ruiz-Patiño A, Arrieta O, Rolfo C. Overcoming TKI resistance in fusion-driven NSCLC: new generation inhibitors and rationale for combination strategies. Transl Lung Cancer Res. 2020 Dec;9(6):2581-2598.
4.264 Arrieta O, Lara-Mejía L, Bautista-GonzÁlez E, Heredia D, Turcott JG, BarrÓn F, Ramos-Ramírez M, Cabrera-Miranda L, Salinas Padilla MÁ, Aguerrebere M, Cardona AF, Rolfo C, Arroyo-HernÁndez M, Soto-Pérez-de-Celis E, Baéz-Saldaña R. Clinical Impact of the COVID-19 Pandemic in Mexican Patients with Thoracic Malignancies
Oncologist. 2021 Dec;26(12):1035-1043
4.265 Turcott JG, Zatarain-Barrón ZL, Cárdenas Fernández D, Castañares Bolaños DT, Arrieta O. Appetite stimulants for patients with cancer: current evidence for clinical practice. Nutr Rev. 2022 Mar 10;80(4):857-873
4.266 Lara-Mejía L, Sánchez-Reyes R, Avilés-Salas A, Arrieta O. A Patient With Newly Diagnosed, Advanced EGFR-Mutated Non-Small Cell Lung Cancer. Oncology (Williston Park). 2020 Jan 15;34(1):21-27.
4.267 Cacho-Díaz B, Cuapaténcatl LD, Rodríguez JA, Garcilazo-Reyes YJ, Reynoso-Noverón N, Arrieta O. Identification of a high-risk group for brain metastases in non-small cell lung cancer patients. J Neurooncol. 2021 Oct;155(1):101-106
4.268 Ruiz-Patiño A, Rodríguez J, Cardona AF, Ávila J, Archila P, Carranza H, Vargas C, Otero J, Arrieta O, Zatarain-Barrón L, Sotelo C, Ordoñez C, García-Robledo JE, Rojas L, Bermúdez M, Gámez T, Mayorga D, Corrales L, Martín C, Recondo G, Mas L, Samtani S, Ricaurte L, Malapelle U, Russo A, Barrón F, Santoyo N, Rolfo C, Rosell R; ONCOLGroup; CLICaP. p.G12C KRAS mutation prevalence in non-small cell lung cancer: Contribution from interregional variability and population substructures among Hispanic. Transl Oncol. 2022 Jan;15(1):101276
4.269 Burgos R, Cardona AF, Santoyo N, Ruiz-Patiño A, Cure-Casilimas J, Rojas L, Ricaurte L, Muñoz Á, Garcia-Robledo JE, Ordoñez C, Sotelo C, Rodríguez J, Zatarain-Barrón ZL, Pineda D, Arrieta O. Case Report: Differential Genomics and Evolution of a Meningeal Melanoma Treated With Ipilimumab and Nivolumab. Front Oncol. 2022 Jan 5;11:691017.
4.270 Garcia-Robledo JE, Rosell R, Ruíz-Patiño A, Sotelo C, Arrieta O, Zatarain-Barrón L, Ordoñez C, Jaller E, Rojas L, Russo A, de Miguel-Pérez D, Rolfo C, Cardona AF. KRAS and MET in non-small-cell lung cancer: two of the new kids on the 'drivers' block. Ther Adv Respir Dis. 2022 Jan-Dec;16:17534666211066064.
4.271 Arrieta O, Molina-Romero C, Cornejo-Granados F, Marquina-Castillo B, Avilés-Salas A, López-Leal G, Cardona AF, Ortega-Gómez A, Orozco-Morales M, Ochoa-Leyva A, Hernandez-Pando R. Clinical and pathological characteristics associated with the presence of the IS6110 Mycobacterim tuberculosis transposon in neoplastic cells from non-small cell lung cancer patients. Sci Rep. 2022 Feb 9;12(1):2210
4.272 Whisenant JG, Baena J, Cortellini A, Huang LC, Lo Russo G, Porcu L, Wong SK, Bestvina CM, Hellmann MD, Roca E, Rizvi H, Monnet I, Boudjemaa A, Rogado J, Pasello G, Leighl NB, Arrieta O, Aujayeb A, Batra U, Azzam AY, Unk M, Azab MA, Zhumagaliyeva AN, Gomez-Martin C, Blaquier JB, Geraedts E, Mountzios G, Serrano-Montero G, Reinmuth N, Coate L, Marmarelis M, Presley CJ, Hirsch FR, Garrido P, Khan H, Baggi A, Mascaux C, Halmos B, Ceresoli GL, Fidler MJ, Scotti V, Métivier AC, Falchero L, Felip E, Genova C, Mazieres J, Tapan U, Brahmer J, Bria E, Puri S, Popat S, Reckamp KL, Morgillo F, Nadal E, Mazzoni F, Agustoni F, Bar J, Grosso F, Avrillon V, Patel JD, Gomes F, Ibrahim E, Trama A, Bettini AC, Barlesi F, Dingemans AM, Wakelee H, Peters S, Horn L, Garassino MC, Torri V; TERAVOLT study group. A definitive prognostication system for patients with thoracic malignancies diagnosed with COVID-19: an update from the TERAVOLT registryJ Thorac Oncol. 2022 Jan 24:S1556-0864(22)00033-8.
4.273 Peralta-Arrieta I, Trejo-Villegas OA, Armas-López L, Ceja-Rangel HA, Ordóñez-Luna MDC, Pineda-Villegas P, González-López MA, Ortiz-Quintero B, Mendoza-Milla C, Zatarain-Barrón ZL, Arrieta O, Zúñiga J, Ávila-Moreno F. Failure to EGFR-TKI-based therapy and tumoural progression are promoted by MEOX2/GLI1-mediated epigenetic regulation of EGFR in the human lung cancer Eur J Cancer. 2022 Jan;160:189-205
4.274 Arrieta O, Zatarain-Barrón ZL,Turcott GY,et al Association of BMI With Benefit of Metformin Plus Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitors in Patients With Advanced Lung Adenocarcinoma. A Secondary Analysis of a Phase 2 Randomized Clinical Trial. JAMA Oncol . 2022 Mar 1;8(3):477-479
4.275 Arrieta O, Hernández-Pedro N, Maldonado F, Ramos-Ramírez, Zatarain-Barrón Z L, Turcott J G, Barrios-Bernal P, Orozco-Morales M, Flores-Estrada D, Cardona A F, Rolfo C, Gutiérrez-Torres S, Cacho-Díaz B. Nitroglycerin Plus Whole Intracranial Radiation Therapy for Brain Metastases in Non-Small Cell Lung Cancer Patients: A Randomized, Open-Label, Phase 2 Clinical Trial. Int J Radiat Oncol Biol Phys . 2022 Feb 12;S0360-3016(22)00156-0
4.276 Passaro A, Leighl N, Blackhall F, Popat S, Kerr K, Ahn MJ, Arcila ME, Arrieta O, Planchard D, de Marinis F, Dingemans AM, Dziadziuszko R, Faivre-Finn C, Feldman J, Felip E, Curigliano G, Herbst R, Jänne PA, John T, Mitsudomi T, Mok T, Normanno N, Paz-Ares L, Ramalingam S, Sequist L, Vansteenkiste J, Wistuba II, Wolf J, Wu YL, Yang SR, Yang JCH, Yatabe Y, Pentheroudakis G, Peters S. ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer. Ann Oncol. 2022 May;33(5):466-487.
4.277 Sánchez-Román S, Chavarri-Guerra Y, Vargas-Huicochea I, Alvarez Del Río A, Bernal Pérez P, Morales Alfaro A, Ramirez Maza D, de la O Murillo A, Flores-Estrada D, Arrieta O, Soto-Perez-de-Celis E. Financial Toxicity Among Older Mexican Adults With Cancer and Their Families: A Mixed-Methods Study. JCO Glob Oncol. 2022 Mar;8:e2100324.
4.278 Rosell R, Cardona AF, Arrieta O, González-Cao M. Classification of atypical EGFR mutations in non-small-cell lung cancer. Ann Oncol. 2022 Jun;33(6):571-573.
4.279 Barrios-Bernal P, Hernandez-Pedro N, Orozco-Morales M, Viedma-Rodríguez R, Lucio-Lozada J, Avila-Moreno F, Cardona AF, Rosell R, Arrieta O. Metformin Enhances TKI-Afatinib Cytotoxic Effect, Causing Downregulation of Glycolysis, Epithelial-Mesenchymal Transition, and EGFR-Signaling Pathway Activation in Lung Cancer Cells. Pharmaceuticals (Basel). 2022 Mar 21;15(3):381
4.280 Arrieta O, Zatarain-Barrón ZL, Cardona AF, Corrales L, Martin C, Cuello M. Uniting Latin America Through Research: How Regional Research Can Strengthen Local Policies, Networking, and Outcomes for Patients With Lung Cancer. Am Soc Clin Oncol Educ Book. 2022 Apr;42:1-7.
4.281 Raez LE, Cardona AF, Lopes G, Arrieta O. Challenges in Genetic Testing and Treatment Outcomes Among Hispanics With Lung Cancer. JCO Oncol Pract. 2022 May;18(5):374-377
4.282 Nanjo S, Wu W, Karachaliou N, Blakely CM, Suzuki J, Chou YT, Ali SM, Kerr DL, Olivas VR, Shue J, Rotow J, Mayekar MK, Haderk F, Chatterjee N, Urisman A, Yeo JC, Skanderup AJ, Tan AC, Tam WL, Arrieta O, Hosomichi K, Nishiyama A, Yano S, Kirichok Y, Tan DS, Rosell R, Okimoto RA, Bivona TG. Deficiency of the splicing factor RBM10 limits EGFR inhibitor response in EGFR-mutant lung cancer. J Clin Invest. 2022 Jul 1;132(13):e145099
4.283 Solomon BJ, Bauer TM, Ou SI, Liu G, Hayashi H, Bearz A, Penkov K, Wu YL, Arrieta O, Jassem J, Calella AM, Peltz G, Polli A, Thurm H, Mok T. Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients With ALK-Positive Advanced Non-Small-Cell Lung Cancer From the Phase III CROWN Study. J Clin Oncol. 2022 May 23:JCO2102278
4.284 Bestvina CM, Whisenant JG, Torri V, Cortellini A, Wakelee H, Peters S, Roca E, De Toma A, Hirsch FR, Mamdani H, Halmos B, Arrieta O, Metivier AC, Fidler MJ, Rogado J, Presley CJ, Mascaux C, Genova C, Blaquier JB, Addeo A, Finocchiaro G, Khan H, Mazieres J, Morgillo F, Bar J, Aujayeb A, Mountzios G, Scotti V, Grosso F, Geraedts E, Zhumagaliyeva AN, Horn L, Garassino MC, Baena J; TERAVOLT study group. Coronavirus Disease 2019 Outcomes, Patient Vaccination Status, and Cancer-Related Delays During the Omicron Wave: A Brief Report From the TERAVOLT Analysis. JTO Clin Res Rep. 2022 Aug;3(8):100335.
4.285 de Miguel-Perez D, Russo A, Arrieta O, Ak M, Barron F, Gunasekaran M, Mamindla P, Lara-Mejia L, Peterson CB, Er ME, Peddagangireddy V, Buemi F, Cooper B, Manca P, Lapidus RG, Hsia RC, Cardona AF, Naing A, Kaushal S, Hirsch FR, Mack PC, Serrano MJ, Adamo V, Colen RR, Rolfo C. Extracellular vesicle PD-L1 dynamics predict durable response to immune-checkpoint inhibitors and survival in patients with non-small cell lung cancer. J Exp Clin Cancer Res. 2022 Jun 2;41(1):186
4.286 Cardona AF, Mejía SA, Viola L, Chamorro DF, Rojas L, Ruíz-Patiño A, Serna A, Martínez S, Muñoz Á, Rodríguez J, García-Robledo JE, Pino LE, Zatarain-Barrón ZL, Arrieta O. Lung Cancer in Colombia. J Thorac Oncol. 2022 Aug;17(8):953-960.
4.287 Ordóñez-Reyes C, Garcia-Robledo JE, Chamorro DF, Mosquera A, Sussmann L, Ruiz-Patiño A, Arrieta O, Zatarain-Barrón L, Rojas L, Russo A, de Miguel-Perez D, Rolfo C, Cardona AF. Bispecific Antibodies in Cancer Immunotherapy: A Novel Response to an Old Question. Pharmaceutics. 2022 Jun 11;14(6):1243
4.288 Rojas L, Mayorga D, Ruiz-Patiño A, Rodríguez J, Cardona AF, Archila P, Avila J, Bravo M, Ricaurte L, Sotelo C, Arrieta O, Zatarain-Barrón ZL, Carranza H, Otero J, Vargas C, Barrón F, Corrales L, Martín C, Recondo G, Pino LE, Bermudez MA, Gamez T, Ordoñez-Reyes C, García-Robledo JE, de Lima VC, Freitas H, Santoyo N, Malapelle U, Russo A, Rolfo C, Rosell R; CLICaP. Human papillomavirus infection and lung adenocarcinoma: special benefit is observed in patients treated with immune checkpoint inhibitors. ESMO Open. 2022 Aug;7(4):100500
4.289 Cordeiro de Lima VC, Corassa M, Saldanha E, Freitas H, Arrieta O, Raez L, Samtani S, Ramos M, Rojas C, Burotto M, Chamorro DF, Recondo G, Ruiz-Patiño A, Más L, Zatarain-Barrón L, Mejía S, Nicolas Minata J, Martín C, Bautista Blaquier J, Motta Guerrero R, Aliaga-Macha C, Carracedo C, Ordóñez-Reyes C, Garcia-Robledo JE, Corrales L, Sotelo C, Ricaurte L, Santoyo N, Cuello M, Jaller E, Rodríguez J, Archila P, Bermudez M, Gamez T, Russo A, Viola L, Malapelle U, de Miguel Perez D, Rolfo C, Rosell R, Cardona AF. STK11 and KEAP1 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value among Hispanics (STRIKE registry-CLICaP). Lung Cancer. 2022 Aug;170:114-121
4.290 Cardona AF, Ruiz-Patiño A, Recondo G, Martín C, Raez L, Samtani S, Minata JN, Blaquier JB, Enrico D, Burotto M, Ordóñez-Reyes C, Chamorro DF, Garcia-Robledo JE, Corrales L, Zatarain-Barrón ZL, Más L, Sotelo C, Ricaurte L, Santoyo N, Cuello M, Mejía S, Jaller E, Vargas C, Carranza H, Otero J, Rodríguez J, Archila P, Bermudez M, Gamez T, Cordeiro de Lima V, Freitas H, Russo A, Polo C, Malapelle U, Perez DM, Rolfo C, Viola L, Rosell R, Arrieta O. Mechanisms of Resistance to First-Line Osimertinib in Hispanic Patients With EGFR Mutant Non-Small Cell Lung Cancer (FRESTON-CLICaP). Clin Lung Cancer. 2022 Sep;23(6):522-531
4.291 Gutierrez Torres S, Maldonado Magos F, Turcott JG, Hernandez-Martinez JM, Cacho-Díaz B, Cardona AF, Mota-García A, Lozano Ruiz F, Ramos-Ramirez M, Arrieta O. Re-irradiation in patients with progressive or recurrent brain metastases from extracranial solid tumors: A novel prognostic index. Cancer Med. 2022 Jun 30
4.292 Cardona AF, González-Cao M, Arrieta O, Rosell R. Location of EGFR exon 20 insertions matters. Cancer Cell. 2022 Jul 11;40(7):705-708
4.293 Belgers V, Röttgering JG, Douw L, Klein M, Ket JCF, van de Ven PM, Würdinger T, van Linde ME, Niers JM, Weber M, Olde Rikkert MG, Lopez-Sendon J, Arrieta O. Cannabinoids to Improve Health-Related Quality of Life in Patients with Neurological or Oncological Disease: A Meta-AnalysisSvendsen KB, Chagas MHN, de Almeida CMO, Kouwenhoven MCM, de Witt Hamer PC. Cannabis Cannabinoid Res. 2022 Jul 21.
4.294 Barrios-Bernal P, Zatarain-Barrón ZL, Hernández-Pedro N, Orozco-Morales M, Olivera-Ramírez A, Ávila-Moreno F, Colín-González AL, Cardona AF, Rosell R, Arrieta O. Will We Unlock the Benefit of Metformin for Patients with Lung Cancer? Lessons from Current Evidence and New Hypotheses. Pharmaceuticals (Basel). 2022 Jun 24;15(7):786.
4.295 Arrieta O, Celis MA, Islas S, Lifshitz A, Mansilla A, Martínez I, Mimenza A, Moreno M, Reyes-Sánchez A, Rocha L, Ruiz-Argüelles G, Soda A, Toussaint S, Verástegui E, Vilar-Compte D, Sotelo J. New interaction modalities between the pharmaceutical industry and physicians. Gac Med Mex. 2022;158(3):157-159
4.296 Raez LE, Arrieta O, Chamorro DF, Soberanis-Piña PD, Corrales L, Martín C, Cuello M, Samtani S, Recondo G, Mas L, Zatarain-Barrón ZL, Ruíz-Patiño A, García-Robledo JE, Ordoñez-Reyes C, Jaller E, Dickson F, Rojas L, Rolfo C, Rosell R, Cardona AF. Durvalumab After Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer: Inferior Outcomes and Lack of Health Equity in Hispanic Patients Treated With PACIFIC Protocol (LA1-CLICaP). Front Oncol. 2022 Jul 12;12:904800.
4.297 Remon J, Levy A, Singh P, Hendriks LEL, Aldea M, Arrieta O. Current challenges of unresectable stage III NSCLC: are we ready to break the glass ceiling of the PACIFIC trial?. Ther Adv Med Oncol. 2022 Jul 26;14:17588359221113268.
4.298 Jensen LR, Maier AD, Lomstein A, Graillon T, Hrachova M, Bota D, Ruiz-Patiño A, Arrieta O, Cardona AF, Rudà R, Furtner J, Roeckle U, Clement P, Preusser M, Scheie D, Broholm H, Kristensen BW, Skjøth-Rasmussen J, Ziebell M, Munch TN, Fugleholm K, Walter MA, Mathiesen T, Mirian C. Somatostatin analogues in treatment-refractory meningioma: a systematic review with meta-analysis of individual patient data Neurosurg Rev. 2022 Oct;45(5):3067-3081
4.299 Cacho-Díaz B, Cuapantécatl LD, Garcilazo-Reyes YJ, Cabrera-Miranda L, Hernandez-Martinez JM, Targeted Therapies and Utility of the Lung-molGPA in Non-Small-Cell Lung Cancer Patients with Brain Metastases Arrieta O. Oncology. 2022;100(10):542-554.
4.300 Caglevic C, Rolfo C, Gil-Bazo I, Cardona A, Sapunar J, Hirsch FR, Gandara DR, Morgan G, Novello S, Garassino MC, Mountzios G, Leighl NB, Bretel D, Arrieta O, Addeo A, Liu SV, Corrales L, Subbiah V, Aboitiz F, Villarroel-Espindola F, Reyes-Cosmelli F, Morales R, Mahave M, Raez L, Alatorre J, Santos E, Ubillos L, Tan DSW, Zielinski C. The Armed Conflict and the Impact on Patients With Cancer in Ukraine: Urgent Considerations. JCO Glob Oncol. 2022 Aug;8:e2200123
4.301 Gonzalez-Ling A, Galindo Vázquez O, Espinoza Bello M, Robles R, Rascón-Gasca ML, Lara-Mejía L, Heredia D, Arrieta O. Quality of life, anxiety, depression, and distress in patients with advanced and metastatic lung cancer. Palliat Support Care. 2022 Oct 10:1-8
4.302 Avilés-Salas A, Flores-Estrada D, Lara-Mejía L, Catalán R, Cruz-Rico G, Orozco-Morales M, Heredia D, Bolaño-Guerra L, Soberanis-Piña PD, Varela-Santoyo E, Cardona AF, Arrieta O. Modifying factors of PD-L1 expression on tumor cells in advanced non-small-cell lung cancer. Thorac Cancer. 2022 Oct 31
4.303 Heredia D, Mas L,Cardona AF, Oyervides V, Motta Guerrero R, Galvez-Nino M, Lara-Mejía L, Aliaga-Macha C, Carracedo C, Varela-Santoyo E, Ramos-Ramírez M, Davila-Dupont D, Martínez J, Cruz-Rico G, Remon J, Arrieta O. A high number of co-occurring genomic alterations detected by NGS is sociated with worse clinical outcomes in advanced EGFR-mutant lung adenocarcinoma: Data from LATAM population.. Volume 174, December 2022, Pages 133-140
4.304. Leal YA,Torres J,Gamboa R,Mantilla-Morales A, Piña-Sanchez Patricia, Arrieta O, Bonifaz L, Meneses A, Duque C, Piñeros Marion. Cancer Incidence in Merida, Mexico 2015-2018: First Report from the Population-based Cancer Registry. Arch Med Res. 2022 Dec;53(8):859-866
4.305 de Miguel-Perez D, Russo A, Gunasekaran M, Buemi F, Hester L, Fan X, Carter-Cooper BA, Lapidus RG, Peleg A, Arroyo-Hernández M, Cardona AF, Naing A, Hirsch FR, Mack PC, Kaushal S, Serrano MJ, Adamo V, Arrieta O, Rolfo C. Baseline extracellular vesicle TGF-β is a predictive biomarker for response to immune-checkpoint inhibitors and survival in non-small-cell lung cancer. Cancer. 2022 Dec 9
4.306 Ortiz Valdez E , Rangel Escareño C, Matus Santos J A, Vázquez Romo R, Guijosa A, Villarreal Garza C, Arrieta O, Rodríguez Bautista R, Claudia H. Caro Sánchez And Ortega Gómez A. Characterization of triple negative breast cancer gene expression profiles in Mexican patients. Molecular And Clinical Oncology 18: 5, 2023.
